NO862528D0 - Metode for aa forhindre ocular hypertensjon, behandling av glaucoma og behandling av ocular hypertensjon. - Google Patents

Metode for aa forhindre ocular hypertensjon, behandling av glaucoma og behandling av ocular hypertensjon.

Info

Publication number
NO862528D0
NO862528D0 NO862528A NO862528A NO862528D0 NO 862528 D0 NO862528 D0 NO 862528D0 NO 862528 A NO862528 A NO 862528A NO 862528 A NO862528 A NO 862528A NO 862528 D0 NO862528 D0 NO 862528D0
Authority
NO
Norway
Prior art keywords
treatment
ocular hypertension
glaucoma
prevent
hypertension
Prior art date
Application number
NO862528A
Other languages
English (en)
Inventor
Paul A Knepper
Original Assignee
Paul A Knepper
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paul A Knepper filed Critical Paul A Knepper
Publication of NO862528D0 publication Critical patent/NO862528D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO862528A 1984-10-22 1986-06-23 Metode for aa forhindre ocular hypertensjon, behandling av glaucoma og behandling av ocular hypertensjon. NO862528D0 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/663,507 US4617299A (en) 1983-12-19 1984-10-22 Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension

Publications (1)

Publication Number Publication Date
NO862528D0 true NO862528D0 (no) 1986-06-23

Family

ID=24662106

Family Applications (1)

Application Number Title Priority Date Filing Date
NO862528A NO862528D0 (no) 1984-10-22 1986-06-23 Metode for aa forhindre ocular hypertensjon, behandling av glaucoma og behandling av ocular hypertensjon.

Country Status (6)

Country Link
US (1) US4617299A (no)
EP (1) EP0199768A4 (no)
JP (1) JPS62501002A (no)
DK (1) DK294286A (no)
NO (1) NO862528D0 (no)
WO (1) WO1986002554A1 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812448A (en) * 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5223493A (en) * 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US5446177A (en) * 1984-12-28 1995-08-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4945089A (en) * 1987-12-29 1990-07-31 Alcon Laboratories, Inc. Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids
US5358943A (en) * 1987-12-29 1994-10-25 Clark Abbot F Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5407926A (en) * 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
DE69033541D1 (de) * 1989-09-25 2000-06-15 Univ Utah Res Found Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugung
US5919465A (en) * 1989-09-25 1999-07-06 University Of Utah Research Foundation Methods for augmenting immunological responses through the administration of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S)
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
USRE34578E (en) * 1990-05-07 1994-04-05 Lubkin; Virginia Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
FR2679139B1 (fr) * 1991-07-17 1995-03-17 Theramex Nouvelles compositions pharmaceutiques destinees a l'application oculaire renfermant un derive androstenique et leur procede de preparation.
KR100249555B1 (ko) * 1991-06-18 2000-04-01 루게쥐농 프랑스와 스테로이드를 함유하는 안구용 조성물, 및 녹내장 치료에 이들 조성물을 사용하는 방법
ATE232540T1 (de) * 1991-11-22 2003-02-15 Alcon Lab Inc Angiostatische steroide
AU674681B2 (en) * 1992-04-21 1997-01-09 Schepens Eye Research Institute, Inc., The Ocular androgen therapy in Sjogren's syndrome
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5849879A (en) * 1994-11-03 1998-12-15 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5606043A (en) 1994-11-03 1997-02-25 The Regents Of The University Of California Methods for the diagnosis of glaucoma
US5789169A (en) * 1994-11-03 1998-08-04 Regents Of The University Of California Methods for the diagnosis of glaucoma
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
WO1998024449A1 (en) * 1996-12-05 1998-06-11 Gerald Fenichel The use of oxandrolone in the treatment of a neurological disorder
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6090798A (en) * 1997-12-19 2000-07-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with glucocorticoid antagonists
US6113542A (en) * 1998-12-15 2000-09-05 Hyman; George F. Diagnostic apparatus and method to provide effective intraocular pressure based on measured thickness of the cornea
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
US6410045B1 (en) 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
US20030119000A1 (en) * 2001-11-05 2003-06-26 Jon Polansky Methods to screen and treat individuals with glaucoma or the propensity to develop glaucoma
WO2003090662A2 (en) * 2002-04-25 2003-11-06 Rapidheal, Inc. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
US20030203032A1 (en) * 2002-04-25 2003-10-30 Schultz Clyde L. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
WO2004093882A1 (ja) * 2003-04-18 2004-11-04 Advanced Medicine Research Institute 眼に適用する疾患治療剤
WO2004091630A1 (ja) * 2003-04-18 2004-10-28 Advanced Medicine Research Institute 眼に適用する疾患治療剤
US8030284B2 (en) * 2004-08-23 2011-10-04 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
WO2007009087A2 (en) * 2005-07-12 2007-01-18 Dmi Biosciences, Inc. Methods and products for treatment of diseases
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
GB0521716D0 (en) * 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
EA027524B1 (ru) 2009-06-22 2017-08-31 Ампио Фармасьютикалс, Инк. Способ ингибирования гиперпроницаемости сосудов при отеке маклы
CN103403184A (zh) 2010-12-23 2013-11-20 劳伦特·亚历山大 用于获得适用于患有或易患一种或多种基因相关眼部障碍或疾病的人类个体的光学装置的方法
CN104781402A (zh) 2012-09-05 2015-07-15 西伦蒂斯私人股份公司 siRNA及其在用于治疗和/或预防眼部病症的方法和组合物中的应用
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN104968350A (zh) 2012-12-19 2015-10-07 安皮奥制药股份有限公司 疾病的治疗方法
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
US10011837B2 (en) 2014-03-04 2018-07-03 Sylentis Sau SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
DE102015107307B3 (de) * 2015-05-11 2016-09-08 Labor L + S Aktiengesellschaft Optisches Verfahren zur Gehaltsbestimmung von Hyaluronsäure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461829A (en) * 1981-09-14 1984-07-24 Miles Laboratories, Inc. Homogeneous specific binding assay element and lyophilization production method
DK493984A (da) * 1983-10-24 1985-04-25 Univ Texas Hybrid celle linier, monokloniske antistoffer frembragt med disse samt diagnosemetode under anvendelse af antistofferne

Also Published As

Publication number Publication date
DK294286D0 (da) 1986-06-23
DK294286A (da) 1986-08-21
US4617299A (en) 1986-10-14
EP0199768A4 (en) 1989-04-26
WO1986002554A1 (en) 1986-05-09
EP0199768A1 (en) 1986-11-05
JPS62501002A (ja) 1987-04-23

Similar Documents

Publication Publication Date Title
NO862528D0 (no) Metode for aa forhindre ocular hypertensjon, behandling av glaucoma og behandling av ocular hypertensjon.
AU560189B2 (en) Treatment of ocular hypertension and glaucoma
AU1391683A (en) Treatment of ocular hypertension and glaucoma
DE3788984T2 (de) Verwendung von Prostaglandin-D2-aktiven-Substanzen zur Behandlung von Augen-Hypertension und von Glaukom.
NO164720C (no) Fremgangsmaate for behandling av titanlegeringer.
NO875487D0 (no) Fremgangsmaate for selektiv behandling av en undergrunnsformasjon.
NO875252L (no) Fremgangsmaate og system for behandling av dispersjoner av borkaks og lignende.
IE800102L (en) N-benzylimidazoles
DE3785602D1 (de) Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom.
NO157146C (no) Analogifremgangsmaate ved fremstilling av terapeutisk, aktive derivater av morfolinyl-daunorbicin og morfolinyl-doksorubicin.
DK19785A (da) Terapeutisk og/eller praeventiv ophthalmisk oploesning til intraoculaer hypertension og glaucoma
NO163785C (no) Fremgangsmaate for behandling av korn-orientert staal.
NO854942L (no) Fremgangsmaate for fremstilling av terapeutisk aktive, benzotiofener og benzofuraner.
NO159014C (no) Fremgangsmaate og anordning for behandling av vann.
NO861596L (no) Fremgangsmaate for behandling av vann, samt innretning for fremgangsmaatens utfoerelse.
NO161376C (no) Fremgangsmaate for kopolymerisering av etylen og 1,3-butadien.
NO161917C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive derivater av tieno- og furo-(2,3-c)-pyrroler.
GB2197199B (en) Medicament for treatment of pregnancy-induced hypertension.
AU521715B2 (en) 6 1 n-alkyl and 6 1, 5' din-alkyl derivatives of fortimycins aand b
NO884635D0 (no) Fremgangsmaate for behandling av most.
FI875322A0 (fi) Foerfarande foer framstaellning av 17a--hydroxi-d-homo-1,4-pregnadien-3,20-dion.
NO854925L (no) Fremgangsmaate for fremstilling av akrylamid og n-substituerte akrylamider.
NO891987D0 (no) Fremgangsmaate for fremstilling av n-substituerte fenyltioaniliner, fenylsulfinylaniliner og fenylsulfonylaniliner.
NO870708L (no) Elektrode og framgangsmÿte for tilvirkning av denne.
ATE88636T1 (de) Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augenhypertension und glaukom.